Evidence map›Paper›PMID 36198021›Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Effectiveness and Safety of Direct Oral Anticoagulants in Thai Patients with Atrial Fibrillation: A Real-World Retrospective Cohort Study.

Saowaluk Srikajornlarp, Montawatt Amnueypol, Prin Vathesatogkit, Pawin Numthavaj, Artit Ungkanont, Khanchit Likittanasombat, Oraluck Pattanaprateep, Pantep Angchaisuksiri, Kochawan Boonyawat

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Saowaluk SrikajornlarpDepartment of Medicine, 26687Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.ORCID 0000-0002-5139-0606
Montawatt AmnueypolDepartment of Medicine, 26687Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Prin VathesatogkitDepartment of Medicine, 26687Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Pawin NumthavajDepartment of Clinical Epidemiology and Biostatistics, 26687Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Artit UngkanontChakri Naruebodindra Medical Institute, 26687Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.
Khanchit LikittanasombatDepartment of Medicine, 26687Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Oraluck PattanaprateepDepartment of Clinical Epidemiology and Biostatistics, 26687Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Pantep AngchaisuksiriDepartment of Medicine, 26687Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Kochawan BoonyawatDepartment of Medicine, 26687Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Mahidol University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDirect oral anticoagulants (DOACs) are commonly used to prevent stroke and systemic embolism in patients with atrial fibrillation (AF). However, studies into their effectiveness and safety in the Thai population have so far been limited.

objectivesTo study the effectiveness and safety of warfarin and DOACs among Thai AF patients.

methodsA retrospective cohort study was conducted on AF patients at Ramathibodi Hospital from 2013 to 2018. All patients were followed for at least 1 year. Relevant clinical information was collected and compared between AF patient groups receiving warfarin, dabigatran, rivaroxaban, and apixaban. The primary outcome was a composite of major bleeding, ischemic stroke, and systemic thromboembolism. The secondary outcomes were all-cause mortality and disease-specific mortality caused by major bleeding, ischemic stroke, and systemic thromboembolism.

resultsA total of 1680 AF patients were enrolled in the study (warfarin 1193, apixaban 140, dabigatran 193, rivaroxaban 114). The estimated incidence of composite outcome was 16% [95% CI, 14-18%] and 12.4% [95% CI, 9.4-15.3%] in the warfarin and DOAC group, respectively, given a number needed to treat of 28 [95% CI, 3-52]. Compared with warfarin, DOACs were associated with both lower rate of all-cause mortality (4.9% [22/447] vs 8% [98/1193]) and lower disease-specific mortality (0.4% [2/447] and 1% [12/1193]).

conclusionsThis study suggests DOACs were associated with a lower risk of major bleeding, ischemic stroke, and systemic thromboembolism compared to warfarin in Thai patients with AF. Patients receiving DOAC also had a lower rate of all-cause mortality and disease-specific mortality.

Indexed as

Atrial FibrillationIschemic StrokeStrokeThromboembolismAdministration, OralAnticoagulantsDabigatranHemorrhageHumansRetrospective StudiesRivaroxabanThailandWarfarinAnticoagulantsDabigatranRivaroxabanWarfarinanticoagulantsatrial fibrillationdirect oral anticoagulantsmajor bleedingstrokethromboembolismwarfarin

Identifiers

PMID36198021
PMCPMC9537480
OpenAlexW4302763309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.